ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer

A subset of lung cancers is dependent on the anaplastic lymphoma kinase (ALK) oncogene for survival, a mechanism that is exploited by the use of the ALK inhibitor crizotinib. Despite exceptional initial tumor responses to ALK inhibition by crizotinib, durable clinical response is limited and the eme...

Descripción completa

Detalles Bibliográficos
Autores principales: Pilling, Amanda B., Kim, Jihye, Estrada-Bernal, Adriana, Zhou, Qiong, Le, Anh T., Singleton, Katherine R., Heasley, Lynn E., Tan, Aik Choon, DeGregori, James, Doebele, Robert C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823650/
https://www.ncbi.nlm.nih.gov/pubmed/29507657
http://dx.doi.org/10.18632/oncotarget.24260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823650/
https://www.ncbi.nlm.nih.gov/pubmed/29507657
http://dx.doi.org/10.18632/oncotarget.24260

Ejemplares similares